Veracyte, Inc. , a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical ...

Intelligently searches through manuals, troubleshooting guides, and service history to answer technician questions and proactively recommend service resolutions ...

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...

Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...

Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Sarepta Therapeutics, Inc. (NASDAQ:SRPT). ROE or return on equity is a useful tool to assess how effectively a ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...